GlassScriptPhysician profile
Keith R Baker
NPI 1538271267
$3,021.64
in general payments reported to CMS, 2019-2025
32 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $860 · 2021: $458 · 2022: $137 · 2023: $79.66 · 2024: $198 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.10 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.78 | 2019-2024 | Airsupra |
| Amgen INC. | $245.91 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $234.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $208.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $197.27 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $176.63 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.25 | 2020-2025 | Caplyta |
| Allergan, INC. | $161.71 | 2019-2020 | |
| Novo Nordisk INC | $159.94 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $148.69 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Endologix LLC | $105.91 | 2024 | Alto Abdominal Stent Graft System |
| Otsuka America Pharmaceutical, INC. | $91.88 | 2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $88.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $72.17 | 2019-2021 | |
| Mylan Specialty L.P. | $65.64 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.59 | 2019-2020 | |
| Amarin Pharma, INC. | $51.54 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.27 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $47.22 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $37.26 | 2022-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $33.92 | 2019-2021 | |
| Dexcom, INC. | $25.42 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $17.89 | 2025 | Korlym |
| Intercept Pharmaceuticals, INC. | $15.81 | 2024 | |
| Circassia INC. | $15.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.60 | 2021 | |
| Gilead Sciences, INC. | $12.89 | 2020 | |
| Phadia US INC. | $12.55 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.26 | 2020 | |
| Eisai INC. | $11.55 | 2021 | |
| Daiichi Sankyo INC. | $11.53 | 2020 | |
| Abbvie INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.